Alliance of Community Health Plans, Inc. PAC, Inc.

What Alliance of Community Health Plans, Inc. lobbies on 2026 reports

Besides giving through its PAC, Alliance of Community Health Plans, Inc. pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.

Spent on lobbying in 2026

$1.9M

Quarterly reports read

8

Topics it lobbied on

Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.

• Health Issuesin 6 report entries

  In its own words

  • General Health Care Issues: Advocated on prescription drugs costs, including advocating for the transparency of PBMs and support for the Fair Accountability and Innovative Research (FAIR) Act;
  • Advocated for patent reform and educated on the utilization of GLP-1s drugs;
  • Advocated for the elimination of the separate interchangeability designation for biosimilars.
  • Mental and Behavioral Health: advocated in support of integration, collaborative care and access to mental and behavioral health services; advocated for greater access to mental and behavioral health services overall; advocated for greater access to tele-mental health services; advocated on mental health parity.
  • Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instances of inappropriate or low-value care;
  • Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements.
  • Advocated on prior authorization criteria requirements that are realistic for community-based health plans.
  • General Health Care Issues: Prescription Drug Pricing: Advocated on prescription drug costs, including PBM transparency; advocated in support of the Fair Accountability and Innovative Research (FAIR) Act; advocated for patent reform and on access to and utilization of GLP-1 drugs; and advocated for elimination of the separate interchangeability designation for biosimilars.
  • Mental and Behavioral Health: Advocated for improved access to mental and behavioral health services, including integrated care and tele-mental health; advocated on federal mental health parity requirements.
  • Prior Authorization: Advocated for electronic prior authorization policies that reduce administrative burden, improve timely access to appropriate care and support patient safety; advocated for reciprocal requirements and accountability for health plans and providers to support effective adoption of electronic prior authorization; advocated for implementation timelines, technical standards and reporting requirements that recognize the operational and resource constraints of smaller, community-based health plans.
  • Issues related to healthcare; Medicare Advantage and Medicaid

  Read everything filed under Health Issues

  Offices it contacted

  • HOUSE OF REPRESENTATIVES
  • SENATE
  • Centers For Medicare and Medicaid Services (CMS)
  • Executive Office of the President (EOP)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
• Medicare/Medicaidin 6 report entries

  In its own words

  • Medicare & Medicaid Issues: Medicare Advantage (Part C) and Prescription Drug (Part D) programs including quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs).
  • Medicaid: Advocated on the implementation of the Medicaid provisions in the One Big Beautiful Bill Act;
  • Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee.
  • Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment.
  • Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model; advocated for an end to patent thickets which are a barrier to lower cost biosimilars and generics entering the market; advocated for a ban on direct-to-consumer advertisements of drugs, including an end to the tax breaks that pharmaceutical manufacturers receive associated with direct-to-consumer ads; advocated for increased transparency requirements on pharmaceutical manufactures to list wholesale acquisition costs in drug ads and for expanded authorities for the Food and Drug Administration to better conduct oversight of direct-to-consumer advertisements.

  Read everything filed under Medicare/Medicaid

Who did the lobbying

The organization’s own reports give its total lobbying costs, including any firms it hired; each firm reports what this client paid it.

• Alliance of Community Health Plans, Inc.Its own staff · 3 reports$1.9M
• S-3 GroupLobbying firm · 3 reports$180K
• Pyxis Partners, LLCLobbying firm · 2 reportsNot reported

Matched by name: these reports are filed for “ALLIANCE OF COMMUNITY HEALTH PLANS, INC.”, found by searching “ALLIANCE OF COMMUNITY HEALTH PLANS”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Oct 27, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.